Why wouldn’t they go for FDA approval in the US first? Aren’t they based in the US with the largest market and better payor mix? UK has socialized medicine- they will never pay close to UCR.
Not sure you REALLY understand healthcare. These are serious questions.
I googled drugbank and found the following for DCVax-L: " This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon."
Almost all the entries were "Not Available"
How are you seeing "a rolling review through either ORBIS/ILAP and thus ... multiple RAs involved"?